SpartaLabs
0
SpartaLabs Research · June 17, 2026

NAD+: A Research Overview

A research-library overview of nicotinamide adenine dinucleotide (NAD+) — its chemistry, biosynthetic classification, regulatory landscape, and discovery history from 1906 to the present. Educational reference.

nad-pluscoenzymeredox-biologynicotinamideniacinamide

Introduction

Nicotinamide adenine dinucleotide (NAD+) is a dinucleotide coenzyme found in all living cells. It functions as an obligate hydride-transfer cofactor for hundreds of oxidoreductase reactions and, in a mechanistically distinct role, serves as a consumed substrate for a class of signaling enzymes that regulate gene expression, DNA repair, and cellular stress responses. The compound exists in two interconvertible redox forms — the oxidized NAD+ and the reduced NADH — and is structurally composed of an adenosine monophosphate unit linked by a pyrophosphate bridge to a nicotinamide mononucleotide unit. This article provides an educational reference summary of NAD+ chemistry, biosynthetic origins, pharmacological classification, and regulatory context.

Background

NAD+ occupies a central position in cellular biochemistry as both a carrier of reducing equivalents in catabolism and a signaling molecule whose intracellular concentration is sensed by a family of NAD+-dependent enzymes. These two roles are biochemically distinct: in redox reactions, NAD+ is regenerated by reoxidation and is not net-consumed; in the signaling role, enzymes such as sirtuins (SIRTs) and poly(ADP-ribose) polymerases (PARPs) cleave the glycosidic bond of NAD+, producing nicotinamide as a byproduct and reducing the total cellular NAD+ pool in the process.

Reviews by Verdin (2015, Science) and by Cantó, Menzies, and Auwerx (2015, Cell Metabolism) summarized evidence that the NAD+ metabolome — the totality of cellular NAD+ and its immediate metabolites — is altered in multiple disease contexts and measurably changes in aged tissues in rodent models [1,2]. Research into the causal role of NAD+ metabolome dynamics in cellular biology represents one of the most active frontiers in contemporary biochemistry. Related mitochondrial biology research has also examined MOTS-c, a mitochondria-derived peptide whose signaling properties have drawn interest in the same metabolic research context.

Chemistry and Structure

NAD+ (CAS 53-84-9; molecular formula C₂₁H₂₇N₇O₁₄P₂; molecular weight 663.4 g/mol) is a dinucleotide composed of two nucleoside monophosphates — adenosine 5'-monophosphate (AMP) and nicotinamide mononucleotide (NMN) — joined by a 3',5'-pyrophosphate linkage. The nicotinamide ring is the chemically reactive moiety: it accepts a hydride ion (H⁻) at the C4 position to form NADH, and releases it upon reoxidation.

The molecule carries a net negative charge at physiological pH and is not membrane-permeant under normal conditions. Intracellular NAD+ is compartmentalized across the cytoplasm, mitochondria, and nucleus, with each pool serving relatively distinct enzymatic networks. The mitochondrial pool is the most abundant in energetically active tissues such as skeletal muscle and cardiac tissue.

A phosphorylated form, NADP+ (nicotinamide adenine dinucleotide phosphate), carries an additional phosphate group at the 2' position of the AMP ribose and functions primarily in anabolic reductive biosynthesis. NADP+ and NAD+ serve largely non-overlapping enzymatic networks despite their structural similarity; this article is restricted to the NAD+/NADH couple.

Pharmacological Classification

NAD+ is classified in biochemical and pharmacological literature as a dinucleotide coenzyme and a pyridine nucleotide. It is not a peptide, hormone, growth factor, or receptor agonist. Its inclusion in the research compound literature reflects its role as a substrate for the sirtuin and PARP families of enzymes — subjects of substantial published investigation in redox biology, DNA damage repair, chromatin remodeling, and cellular metabolism.

In cell biology research, NAD+ precursors — most prominently nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) — have been investigated as a means of manipulating the cellular NAD+ pool in experimental settings, because exogenous NAD+ has limited bioavailability due to poor cellular uptake. Published clinical pharmacokinetic studies of NR (Trammell et al., 2016, Nature Communications) documented that oral NR administration produces measurable, dose-dependent increases in blood NAD+ metabolome constituents in humans [3].

Regulatory Status

NAD+ is an endogenous coenzyme present in all mammalian tissues. It does not hold FDA approval as a therapeutic drug for any indication, consistent with its classification as a research compound. The broader NAD+ precursor landscape has an active regulatory dimension: NR is marketed as a dietary supplement ingredient in the United States under FDA New Dietary Ingredient (NDI) acknowledgment (brand name Tru Niagen). NMN's regulatory position is the subject of ongoing industry and regulatory dialogue following a 2022 FDA citizen petition decision that provisionally placed it closer to the drug-candidate category.

Intravenous administration of NAD+ has been examined in observational and early-phase clinical settings. The NR-SAFE trial (2023, Nature Communications), conducted in Parkinson's disease patients, reported that NR was well-tolerated and measurably elevated cerebral NAD+ as assessed by magnetic resonance spectroscopy — a technically significant advance for non-invasive measurement of NAD+ in human brain tissue. Clinical research on NAD+ precursors continues across multiple Phase I and Phase II investigations in varied disease contexts. The accompanying NAD+ discovery and research history article chronicles this regulatory and scientific landscape in greater detail. Research-grade NAD+ from SpartaLabs is independently third-party tested and supplied with a batch-specific certificate of analysis.

Discovery History

The discovery of NAD+ spans more than a century. In 1906, Arthur Harden and William John Young identified a heat-stable, dialysable cofactor in yeast extract — which they named "cozymase" — required for fermentative activity [4,5]. Harden and Hans von Euler-Chelpin shared the Nobel Prize in Chemistry in 1929 for this foundational work; von Euler-Chelpin confirmed that cozymase was a dinucleotide. Otto Heinrich Warburg subsequently identified the nicotinamide ring as the hydride-accepting moiety in 1936, establishing NAD+ as a central cofactor of respiratory metabolism.

The biosynthetic pathways from dietary niacin were characterized through the Preiss-Handler work of 1958 [6]. A new research era opened in 2000, when Imai, Armstrong, Kaeberlein, and Guarente reported in Nature that the yeast silencing protein Sir2 is an NAD+-dependent histone deacetylase — directly linking NAD+ availability to chromatin regulation and cellular gene expression programs [7]. A fuller account of these milestones appears in the accompanying history article.

References

  1. Verdin E. NAD+ in aging, metabolism, and neurodegeneration. Science. 2015;350(6265):1208–1213. DOI: 10.1126/science.aac4854. https://www.science.org/doi/10.1126/science.aac4854

  2. Cantó C, Menzies KJ, Auwerx J. NAD+ metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus. Cell Metab. 2015;22(1):31–53. PMC4487780. https://pmc.ncbi.nlm.nih.gov/articles/PMC4487780/

  3. Trammell SA, Schmidt MS, Weidemann BJ, Redpath P, Jaksch F, Dellinger RW, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun. 2016;7:12948. DOI: 10.1038/ncomms12948. https://www.nature.com/articles/ncomms12948

  4. Harden A, Young WJ. The alcoholic ferment of yeast-juice. Proc R Soc Lond B. 1906;77(519):405–420. DOI: 10.1098/rspb.1906.0029. https://royalsocietypublishing.org/doi/10.1098/rspb.1906.0029

  5. Harden A, Young WJ. The alcoholic ferment of yeast-juice. Part II — The coferment of yeast-juice. Proc R Soc Lond B. 1906;78(526):369–375. DOI: 10.1098/rspb.1906.0070. https://royalsocietypublishing.org/doi/10.1098/rspb.1906.0070

  6. Preiss J, Handler P. Biosynthesis of diphosphopyridine nucleotide. I. Identification of intermediates. J Biol Chem. 1958;233(2):488–492. https://pubmed.ncbi.nlm.nih.gov/13563526/

  7. Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature. 2000;403(6771):795–800. DOI: 10.1038/35001622. https://pubmed.ncbi.nlm.nih.gov/10693811/

Frequently asked questions

  • What is NAD+?

    Nicotinamide adenine dinucleotide (NAD+) is a dinucleotide coenzyme found in all living cells. It functions as an obligate hydride-transfer cofactor for hundreds of oxidoreductase reactions and as a consumed substrate for signaling enzymes that regulate gene expression, DNA repair, and cellular stress responses.

  • What is the chemical structure of NAD+?

    NAD+ is a dinucleotide composed of two nucleoside monophosphates — adenosine 5'-monophosphate (AMP) and nicotinamide mononucleotide (NMN) — joined by a 3',5'-pyrophosphate linkage. Its molecular formula is C₂₁H₂₇N₇O₁₄P₂ with a molecular weight of 663.4 g/mol (CAS 53-84-9). The nicotinamide ring is the chemically reactive moiety that accepts a hydride ion to form NADH.

  • Is NAD+ FDA approved?

    NAD+ does not hold FDA approval as a therapeutic drug for any indication, consistent with its classification as a research compound. The NAD+ precursor nicotinamide riboside (NR) is marketed as a dietary supplement ingredient under FDA New Dietary Ingredient acknowledgment, while NMN's regulatory position remains subject to ongoing dialogue following a 2022 FDA citizen petition decision.

  • Who discovered NAD+?

    The discovery began in 1906 when Arthur Harden and William John Young identified a heat-stable, dialysable cofactor in yeast extract — which they named "cozymase" — required for fermentative activity. Harden and Hans von Euler-Chelpin shared the Nobel Prize in Chemistry in 1929 for this foundational work. Otto Heinrich Warburg subsequently identified the nicotinamide ring as the hydride-accepting moiety in 1936.

  • What is the difference between NAD+ and NADP+?

    NADP+ (nicotinamide adenine dinucleotide phosphate) carries an additional phosphate group at the 2' position of the AMP ribose compared to NAD+. Despite their structural similarity, NADP+ and NAD+ serve largely non-overlapping enzymatic networks — NAD+ functions primarily in catabolic oxidoreductase reactions and as a substrate for sirtuins and PARPs, while NADP+ functions primarily in anabolic reductive biosynthesis.